These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6133638)

  • 21. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk.
    Abraham WT
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S30-6. PubMed ID: 14564232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Necrotic lesions, ischemia and reperfusion: effects of beta blockers].
    Lechat P
    Arch Mal Coeur Vaiss; 1993 Jul; 86 Spec No 4():85-90. PubMed ID: 7905729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Beta-blocker in secondary prevention of cardiovascular disease].
    Sauer G
    Z Kardiol; 2003 Jan; 92(1):24-30. PubMed ID: 12545298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proceedings of a symposium on beta-blockade and myocardial infarct. London, March 1982.
    Br J Clin Pharmacol; 1982; 14 Suppl 1():1S-64S. PubMed ID: 6126203
    [No Abstract]   [Full Text] [Related]  

  • 26. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction.
    Heller DA; Ahern FM; Kozak M
    Am Heart J; 2000 Oct; 140(4):663-71. PubMed ID: 11011343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the NIH: Implications of the recent beta-blocker clinical trials for patients after myocardial infarction.
    JAMA; 1983 May; 249(18):2482-3. PubMed ID: 6133013
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction.
    Smith DH; Kramer JM; Perrin N; Platt R; Roblin DW; Lane K; Goodman M; Nelson WW; Yang X; Soumerai SB
    Arch Intern Med; 2008 Mar; 168(5):477-83; discussion 483; quiz 447. PubMed ID: 18332291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience.
    Furberg CD; Byington RP
    Circulation; 1983 Jun; 67(6 Pt 2):I98-101. PubMed ID: 6133654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing beta-blocker use after myocardial infarction.
    Howard PA; Ellerbeck EF
    Am Fam Physician; 2000 Oct; 62(8):1853-60, 1865-6. PubMed ID: 11057841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient.
    Fonarow GC
    Am Heart J; 2005 Jun; 149(6):984-93. PubMed ID: 15976779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of time-dependent measures to estimate benefits of beta-blockers after myocardial infarction.
    Levy AR; Tamblyn RM; Abrahamowicz M; McLeod PJ; Fitchett D
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):623-31. PubMed ID: 15362086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic use of beta-adrenergic blockade in survivors of myocardial infarction.
    Rotmensch HH; Vlasses PH; Ferguson RK
    Heart Lung; 1984 Jul; 13(4):366-71. PubMed ID: 6145686
    [No Abstract]   [Full Text] [Related]  

  • 34. Association between functional status and use and effectiveness of beta-blocker prophylaxis in elderly survivors of acute myocardial infarction.
    Vitagliano G; Curtis JP; Concato J; Feinstein AR; Radford MJ; Krumholz HM
    J Am Geriatr Soc; 2004 Apr; 52(4):495-501. PubMed ID: 15066062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blockers in the secondary prevention of myocardial infarction: a review of clinical trials of 12 months or more duration.
    Decorde P
    Pharmatherapeutica; 1984; 3(8):515-25. PubMed ID: 6142464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depression after myocardial infarction: unraveling the mystery of poor cardiovascular prognosis and role of beta-blocker therapy.
    von Känel R; Begré S
    J Am Coll Cardiol; 2006 Dec; 48(11):2215-7. PubMed ID: 17161248
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies.
    Avezum A; Pais P; Flather MD; Anand S; Yusuf S
    Indian Heart J; 1995; 47(2):95-105. PubMed ID: 7590849
    [No Abstract]   [Full Text] [Related]  

  • 38. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WVMI provides follow-up on beta blocker use.
    Schade CP
    W V Med J; 2002; 98(5):183. PubMed ID: 12440164
    [No Abstract]   [Full Text] [Related]  

  • 40. [In which patients is beta blockade in myocardial infarction most effective?].
    Henning R
    Lakartidningen; 1989 Mar; 86(12):1050. PubMed ID: 2564454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.